Natural NS3 resistance polymorphisms occur frequently prior to treatment in HIV-positive patients with acute hepatitis C

Leggewie, Maykea; Sreenu, Vattipally B.a; Abdelrahman, Tamera; M. Leitch, E. Carola; Wilkie, Gavin S.a; Klymenko, Tetyanaa; Muir, Davidb; Thursz, Markc; Main, Janicec; Thomson, Emma C.a,c

doi: 10.1097/QAD.0b013e328363b1f9
Research Letters

NS3 protease inhibitors are set to improve sustained virological response rates in HIV-positive patients with hepatitis C. We measured the prevalence of natural resistance polymorphisms in 38 acutely infected treatment-naive patients using direct and deep sequencing. Twenty six percent of patients (10/38) had a majority variant resistance mutation (in order of frequency; Q80K – 16%, V36M – 5%, T54S – 3%, V55A – 3%, and D168A – 3%). Low-frequency mutations were detected in all samples. Further studies are required to determine threshold levels associated with treatment failure.

aMRC Centre for Virus Research, University of Glasgow, Glasgow

bDepartment of Virology, Imperial College NHS Trust

cDepartment of Medicine, Imperial College London, London, UK.

Correspondence to Emma C. Thomson, MRCP, PhD, MRC University of Glasgow Centre for Virus Research, 8 Church Street, Glasgow G11 5JR, UK. E-mail: emma.thomson@glasgow.ac.uk

Received 24 March, 2013

Revised 21 May, 2013

Accepted 27 May, 2013

© 2013 Lippincott Williams & Wilkins, Inc.